Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:06:56 EST Sat 08 Nov 2025
Enter Symbol
or Name
USA
CA



News for U:TGTX from 2024-11-08 to 2025-11-07 - 29 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2025-11-03 07:00U:TGTXNews ReleaseTG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
2025-10-31 07:30U:TGTXNews ReleaseTG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
2025-10-28 07:30U:TGTXNews ReleaseTG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
2025-09-24 09:10U:TGTXNews ReleaseNew Data for BRIUMVI(TM) Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment
2025-09-10 07:31U:TGTXNews ReleaseTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI(TM) in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
2025-09-08 07:30U:TGTXNews ReleaseTG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
2025-09-04 07:30U:TGTXNews ReleaseTG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
2025-09-03 07:30U:TGTXNews ReleaseTG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program
2025-08-28 08:00U:TGTXNews ReleaseTG Therapeutics to Participate in the Cantor Global Healthcare Conference
2025-08-04 07:00U:TGTXNews ReleaseTG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
2025-07-30 07:30U:TGTXNews ReleaseTG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update
2025-06-06 07:30U:TGTXNews ReleaseTG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
2025-06-02 08:00U:TGTXNews ReleaseTG Therapeutics to Participate in the Jefferies Global Healthcare Conference
2025-05-30 07:30U:TGTXNews ReleaseTG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
2025-05-27 07:30U:TGTXNews ReleaseTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI(TM) in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
2025-05-05 07:00U:TGTXNews ReleaseTG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance
2025-04-30 07:30U:TGTXNews ReleaseTG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update
2025-04-10 07:30U:TGTXNews ReleaseTG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
2025-04-08 07:30U:TGTXNews ReleaseTG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
2025-04-07 07:30U:TGTXNews ReleaseTG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals
2025-03-07 07:30U:TGTXNews ReleaseTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI(TM) (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
2025-03-03 07:00U:TGTXNews ReleaseTG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
2025-02-27 07:30U:TGTXNews ReleaseTG Therapeutics Announces Presentation of Data for BRIUMVI(TM) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
2025-02-26 07:30U:TGTXNews ReleaseTG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update
2025-02-18 07:30U:TGTXNews ReleaseTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI(TM) (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
2025-01-14 07:00U:TGTXNews ReleaseTG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones
2025-01-09 07:30U:TGTXNews ReleaseTG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
2024-11-29 08:00U:TGTXNews ReleaseTG Therapeutics to Participate in the Evercore HealthCONx Conference
2024-11-21 06:00U:TGTXNews ReleaseTG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500(TM)